Tamura M, Ueki Y, Ohtsuka E, Oribe M, Seita M, Oribe K, Ito M
Department of Internal Medicine, Oita Red Cross Hospital, Japan.
Jpn Circ J. 1994 May;58(5):374-7. doi: 10.1253/jcj.58.374.
We report a patient who experienced a reversible prolongation of the QT interval and episodes of syncope while receiving probucol. A 64-year-old woman experienced syncopal attacks 8 and 11 weeks after beginning probucol treatment (500 mg twice daily). The pre-treatment ECG showed a slight prolongation of the corrected QT interval (QTc) (0.46 sec). Her QTc increased to 0.62 sec 12 weeks after beginning probucol treatment and decreased to about the baseline value (0.48 sec) 6 weeks after treatment was discontinued. Probucol is known to prolong the QT interval. A long QT interval has been linked to an increased risk of ventricular arrhythmias, syncope or sudden death. However, clinical reports which causally relate probucol treatment to syncope are very rare. Although an ECG during the episodes of syncope was not available, this patient's syncope might be due to ventricular tachyarrhythmia associated with probucol-induced QT prolongation. This case emphasizes the need for careful evaluation of the QT interval before and during probucol treatment.
我们报告了一名在服用普罗布考期间出现QT间期可逆性延长和晕厥发作的患者。一名64岁女性在开始服用普罗布考治疗（每日两次，每次500mg）后8周和11周出现晕厥发作。治疗前心电图显示校正QT间期（QTc）略有延长（0.46秒）。开始服用普罗布考治疗12周后，她的QTc增加到0.62秒，停药6周后降至约基线值（0.48秒）。已知普罗布考会延长QT间期。QT间期延长与室性心律失常、晕厥或猝死风险增加有关。然而，将普罗布考治疗与晕厥有因果关系的临床报告非常罕见。尽管晕厥发作期间的心电图无法获取，但该患者的晕厥可能是由于普罗布考诱导的QT延长相关的室性快速心律失常所致。该病例强调了在普罗布考治疗前和治疗期间仔细评估QT间期的必要性。
